Minimed Group (FRA:B8S) Current Deferred Revenue: €13 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B8S Minimed Group Inc FRA:B8S
15 GF Score
Price €16.65
! 3 Warning Signs
View Full Analysis

What is Minimed Group Current Deferred Revenue?

Minimed Group FRA:B8S +4.39% 15 Current Deferred Revenue is €13 Mil as of Apr. 2026. GuruFocus rates FRA:B8S with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Minimed Group's current deferred revenue for the quarter that ended in Apr. 2026 was €13 Mil.

Minimed Group Current Deferred Revenue Related Terms

Minimed Group Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Minimed Group's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group Current Deferred Revenue Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Current Deferred Revenue
0.00 10.25 9.79 12.83

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26 Apr26
Current Deferred Revenue Get a 7-Day Free Trial 0.00 9.79 0.00 11.06 12.83
FRA:B8S
15GF Score
Minimed Group Inc FRA:B8S
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €13 Mil mean?
Minimed Group (FRA:B8S) has a Current Deferred Revenue of €13 Mil as of Apr. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Minimed Group and its competitors.
Is Minimed Group's Current Deferred Revenue too high?
Minimed Group's current Current Deferred Revenue is €13 Mil. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Current Deferred Revenue compare to MMSI and NVST?
Minimed Group's Current Deferred Revenue of €13 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Minimed Group and its competitors. Minimed Group's current Current Deferred Revenue is €13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (FRA:B8S) has a current Current Deferred Revenue of €13 Mil. The current Current Deferred Revenue is €13 Mil. Minimed Group's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Minimed Group (FRA:B8S), the current Current Deferred Revenue is €13 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges MMED:USA
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for FRA:B8S

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.65
Price